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Abstract
Background: Ruptured abdominal aortic aneurysm (AAA) is responsible for 1–2% of all male
deaths over the age of 65 years. Early detection of AAA and elective surgery can reduce the
mortality risk associated with AAA. However, many patients will not be diagnosed with AAA and
have therefore an increased death risk due to the untreated AAA. It has been suggested that
population screening for AAA in elderly males is effective and cost-effective. The purpose of this
study was to perform a systematic review of published cost-effectiveness analyses of screening
elderly men for AAA.
Methods: We performed a systematic search for economic evaluations in NHSEED, EconLit,
Medline, Cochrane, Embase, Cinahl and two Scandinavian HTA data bases (DACEHTA and SBU).
All identified studies were read in full and each study was systematically assessed according to
international guidelines for critical assessment of economic evaluations in health care.
Results: The search identified 16 cost-effectiveness studies. Most studies considered only short
term cost consequences. The studies seemed to employ a number of "optimistic" assumptions in
favour of AAA screening, and included only few sensitivity analyses that assessed less optimistic
assumptions.
Conclusion: Further analyses of cost-effectiveness of AAA screening are recommended.
Background
The annual number of deaths attributable to ruptured
abdominal aortic aneurysm (AAA) in Denmark is approx-
imately 400–500 [1,2], corresponding to a mortality of 1–
2% of males aged ≥ 65. Overall mortality from ruptured
AAA is 80–90%; about half of patients die before they
reach hospital [3-5]. Screening programmes that establish
diagnosis through ultrasonography and offer elective AAA
repair have been advocated because most patients die
from undiagnosed ruptured AAA.
Four randomized controlled trials (RCTs) have shown a
reduction in AAA-related mortality from screening pro-
grams aimed at elderly males [6]. An expected reduction
in mortality is not sufficient for a screening program. The
program should be acceptable to patients and, if publicly
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funded, should be "good value for money". That is, the
decision to introduce such screening programs should be
based on health effectiveness (good health outcomes) and
cost-effectiveness (good value for money) [7].
The purpose of this study was to review cost-effectiveness
studies of screening programs for AAA in elderly males,
and to assess the evidence of cost-effectiveness of such
programs.
Methods
Literature review
Systematic searches were undertaken in NHSEED, Econ-
Lit, Medline, Cochrane, Embase, Cinahl, and two Scandi-
navian health technology assessment databases
(DACEHTA and SBU). The search was from 01.01.1997 to
01.06.2008. Search strategies (in Medline, Cinhahl,
Cochrane and Embase) were thesaurus-guided: aortic-
aneurysm-abdominal (MeSH) AND mass-screening
(MeSH), and aortic-aneurysm-abdominal, added sub-
heading "prevention and control". Free text search on
AAA screening was also done. Reference lists of identified
studies and other recent relevant publications were
inspected for additional references.
Inclusion criteria
Only studies in English or Scandinavian languages in
peer-reviewed journals were included. Studies had to be a
full health economic evaluation considering cost and
effects (i.e. analyses of cost-effectiveness, cost-utility, and
cost-benefit) of screening males for AAA.
Analyses
Studies [8-23] were read in full. An assessment was made
according to international guidelines for critical assess-
ment of economic evaluations in health care [7] (Table 1).
Special attention was given to included costs, and an over-
view of relevant cost headings were developed based on
the reviewed articles (Table 2).
Results
Type of economic evaluation
Sixteen studies were included (Table 1). An extended
description of the studies included is available as a web
appendix (see "Additional file 1"). Five were from Scandi-
navia, five from the UK, two from USA and Canada, one
from the Netherlands and one from Japan. Eight studies
were designed as cost-effectiveness studies using objective
health outcomes; eight were cost-utility studies with
health outcomes expressed in quality-adjusted life-years
(QALYs). Six studies were conducted alongside trials
(termed "piggyback" in Table 2): three RCTs, two cohort
studies and one case-control study. Ten studies employed
decision analytic models.
Costs associated with AAA screening
Based on the reviewed studies, the main types of costs
associated with population screening, surveillance and
surgery for AAA have been compiled as shown in Table 2.
There were great variations between the studies in the type
of costs. Most studies included only short-term costs, i.e.
it was implicitly assumed that there is no difference in the
long-term costs between the alternatives. Only three stud-
ies [8,15,18] included long-term costs. The MASS study
[8] and Soisalon-Soininen et al. [15] included costs of
hospital and community care in a follow-up period of 4
years and 17 years, respectively. This included costs of
hospital readmissions, visits to the general practitioner,
outpatient attendances, and variations in patient path-
ways due to surgical complications (e.g. dialysis-depend-
ent renal failure, stroke, myocardial infarction, and major
amputation). Henriksson et al. [18] included an estimate
of the average additional annual health care cost after sur-
gery for AAA for the remaining lifetime of patients.
All studies included the costs of invitation to screening,
ultrasonography, and surgery. Only three of the 16 studies
included private cost to patients (e.g. transportation,
time) [14,17,18]. No study included costs of social serv-
ices (e.g. home help, nursing homes).
Cost amount varied considerably between studies (data
not shown). An example is the cost of ultrasonography in
the MASS study [8], which was more than double the cost
in the study by Lindholt et al. [10] (even if adjusting for
different cost year). Another example was transportation
cost (mobile screening team), which varied by more than
fourfold. The cost of surgery also varied. Differences in
cost estimates can be partly explained by the different
organizational arrangements and different circumstances
due to geography. All studies lacked detailed reporting of
cost estimates, and offered only limited transparency in
cost calculations.
Organizational assumptions underpinning economic 
calculations
Ultrasonography is the "gold standard" for AAA screening,
and has been used in all AAA trials and decision analytic
models. All studies assumed that ultrasonography was
done by a mobile team of hospital specialists. Surveillance
of patients with small AAAs was assumed to be handled
by the same team. There were differences with regard to
the: (i) number and type of screening locations; (ii) aver-
age distances of travel for the team and patients; and (iii)
role of the general practitioner. Organizational models in
all studies were described only superficially, which
restricted transferability.BMC Cardiovascular Disorders 2008, 8:32 http://www.biomedcentral.com/1471-2261/8/32
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Table 1: Studies of cost-effectiveness of AAA screening
Nr. Study Alternative programs ICER* Comments
1 MASS 2002 (UK) [8] Screening of men aged 65–74 
years vs. no systematic screening 
strategy
GBP 28 400 per gained life-year 
or GBP 36 000 per QALY Price 
level: year 2000
Costs outside the health care 
sector not included. Different 
discount rates used for costs and 
effects. QOL after elective surgery 
assumed to be similar to normal 
population.
2 Kim et al. 2008 (UK) [9] Screening of men aged 65–74 
years vs. no systematic screening 
strategy
USD 19 500 per gained life-year 
Price level: year 2004–05
Only short-term hospital costs 
included. QOL after elective 
surgery assumed to be similar to 
normal population.
3 Lindholt et al. 2006 (DK) [10] Screening of males aged 65–73 
years vs. no systematic screening 
strategy
GBP 6 090 per gained life-year or 
GBP 10 793 per saved life Price 
level: year 2004
Only short-term hospital costs 
included. Costs and health effects 
not discounted.
4 Wilmink et al. 2003 (UK) [11] Screening of males aged >50 
years vs. no systematic screening 
strategy
USD 1 173 per gained life-year 
Price level: year 1995
Only short-term hospital costs 
included. Costs and health effects 
not discounted.
5 Hobbs et al. 2004 (UK) [12] Screening of males aged >50 
years vs. no systematic screening 
strategy
GBP 375–655 per gained life-year 
Price level: year?
Only short-term hospital costs 
included. Costs and health effects 
not discounted.
6 Ishikawa et al. 2004 (JP) [13] Screening of males and females 
aged >60 years vs. no systematic 
screening strategy
USD 2 366 per detected AAA 
Price level: year?
Only short-term hospital costs 
included. Costs and health effects 
not discounted.
7 Lindholt et al. 2002 (DK) [14] Screening of males aged 65–73 
years vs. no systematic screening 
strategy
DKK 7 540 per gained life-year or 
DKK 67 855 per saved life Price 
level: year 1998
Only short-term hospital costs 
included. Costs and health effects 
not discounted. Long-term 
survival after elective surgery is 
assumed to be similar to normal 
population. Data for males aged 
65–73 years are used as estimates 
for 65-year-old males.
8 Soisalon et al. 2001 (FI) [15] Screening of first-degree relatives 
vs. no systematic screening 
strategy
USD 6 200 per gained life-year 
Price level: year 1987–89
Targeted screening of familial 
AAA. Only hospital costs 
included.
9 Kim et al. 2007 (UK) [16] Screening of males aged 65 years 
vs. no systematic screening 
strategy
GBP 510 per gained life-year or 
GBP 676 per QALY Price level: 
year 2000
Only short-term hospital costs 
included. Long-term survival and 
QOL after elective surgery is 
assumed to be similar to normal 
population. Data for males aged 
65–74 years used as estimates for 
65-year-old males.
10 Wanhainen et al. 2005 (SE) [17] Screening of males at age 60, 65 
or 70 years vs. no systematic 
screening strategy
USD 10 474 per gained life-year 
or USD 13 900 per QALY 
(results for +65 year old) Price 
level: year 2003
Only short-term hospital costs 
and costs of lost time and 
travelling due to screening 
included. QOL after elective 
surgery assumed to be similar to 
normal population. Data for males 
aged 65–74 years (pooled 
estimates from heterogeneous 
studies) used as estimates for 65-
year-old males.
11 Henrikson et al. 2005 (SE) [18] Screening of men aged 65 years 
vs. no systematic screening 
strategy
EUR 7 760 per gained life-year or 
EUR 9,700 per QALY
Price level: year 2003
QOL after elective surgery 
assumed to be similar to normal 
population. Data for males aged 
65–74 years (pooled estimates 
from heterogeneous studies) used 
as estimates for 65-year-old males.
12 Boll et al. 2003 (NL) [19] Screening of males aged 60–65 
years vs. no systematic screening 
strategy
EUR 1 176 per gained life-years
Price level: year 1997
Only short-term hospital costs 
included. Long-term survival after 
elective surgery assumed to be 
similar to normal population.
13 Lee et al. 2002 (US) [20] Screening of males aged 70 years 
vs. no systematic screening 
strategy
USD 11 215 per QALY
Price level: year?
Only short-term hospital costs 
included. Long-term survival and 
QOL after elective surgery 
assumed to be similar to normal 
population.BMC Cardiovascular Disorders 2008, 8:32 http://www.biomedcentral.com/1471-2261/8/32
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Economic evaluations alongside trials (short-term cost-
effectiveness)
Six economic evaluations were conducted alongside trials
using patient-level data in evaluation of the cost-effective-
ness of AAA screening. Three studies [8-10] used patient-
level data from a RCT with a time perspective of 4, 5 and
7 years. The MASS study [8] estimated the incremental
cost-effectiveness ratio (ICER) to be GBP 28 400 per
gained life-year, or approximately GBP 36 000 per QALY.
The authors concluded that this result was at the margin
of acceptability according to National Health Service
thresholds, but they expected cost effectiveness to
improve over time. Kim et al. [9] used data from MASS
trial after 7 years of follow up to estimate ICER at USD19
000; however this study only included short term hospital
costs. Lindholt et al. [10] estimated ICER to be GBP 6 090
per gained life-year without long-term cost and discount-
ing. The three other studies that used patient-level data
(from local cohort studies or case-control studies) esti-
mated ICER to be in the same order of magnitude, and
suggested that screening may be cost-effective [11-13].
Economic evaluations using decision analytic modelling 
(long-term cost-effectiveness)
Ten studies used decision analytic modelling to estimate
long-term cost-effectiveness of AAA screening. The general
conclusion from these studies was that AAA screening
seems to be cost-effective, but the ICER varies considera-
14 Conelly et al. 2002 (CA) [21] Screening of males and females 
aged >50 years vs. no systematic 
screening strategy
CAD 741 per QALY
Price level: year?
Only short-term hospital costs 
included. Long-term survival and 
QOL after elective surgery 
assumed to be similar to normal 
population.
15 Montreuil et al. 2008 (CA) [22] Screening of males aged 65 years 
vs. no systematic screening 
strategy
CAD 6 194 per QALY
Price level: year 2005
Only short-term hospital costs 
included. QOL after elective 
surgery assumed to be similar to 
normal population. Data for males 
aged 65–74 years used as 
estimates for 65-year-old males.
16 Silverstein et al. 2005 (US) [23] Screening of males at age 65 
years vs. no systematic screening 
strategy
USD 19 720 per QALY
Price level: year?
Only short-term hospital costs 
included. Long-term survival and 
QOL after elective surgery 
assumed to be similar to normal 
population. Data for males aged 
65–74 years used as estimates for 
65-year-old males.
* ICER is not comparable between studies because results are based on different assumptions and methods
Table 1: Studies of cost-effectiveness of AAA screening (Continued)
Table 2: Main types of costs associated with AAA screening
1. Invitation to screening (and re-invitations for non-attenders).
Includes clerical staff time, postage and stationery, cost of obtaining patient details, office space and equipment, overheads.
2. Ultrasonograpgy (and re-scan and surveillance).
Includes clinic staff time, staff travel cost, disposables, annuitization of capital expenditures, maintenance and service contracts, office space/charge 
of locations.
3. Surgery (pre-assessments for suitability, elective aneurysm repairs (as well as emergency surgery for ruptures) hospitalization).
Includes theatre time, time spent in intensive care and general ward, drugs, blood products, non-pathological investigations, graft inserted, and 
overheads.
4. Hospital and community care (short and long term)
Includes readmissions, graft surveillance and secondary procedures after surgery, visits to general practitioner, outpatient attendances and patient 
pathways due to surgical complications (dialysis-dependent renal failure, stroke, myocardial infarction, and major amputation).
5. Patient and family resources.
Includes transportation expenditures, medicine and time cost.
6. Resources in other sectors.
Includes social services (e.g. home help and nursing homes).BMC Cardiovascular Disorders 2008, 8:32 http://www.biomedcentral.com/1471-2261/8/32
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bly and a direct comparison of results is not possible due
to considerable differences in the analytical basis. Studies
employed different methods (types of model, time frame,
and perspective) and different assumptions (sources of
evidence for effect and transition probabilities, and cost
assumptions) for their analysis.
Assumptions about screening effectiveness
Half of the modelling studies were based on evidence of
the effectiveness of AAA screening from RCTs. All used evi-
dence from screening a group of men (typically males
aged 65–79 years) to estimate effectiveness of screening a
single age group (typically 65-year-old males). Other
modelling studies were based on effectiveness data from
trials with lower levels of evidence.
In general, the main advantage of screening is assumed to
be an increase in the number of patients diagnosed with
AAA and offered elective AAA repair. All studies assumed
a constant risk of rupture depending on AAA size. The
gained life-years/QALYs arise because the total number of
elective surgeries increases, and the need for emergency
surgery of ruptured AAA is therefore assumed to decrease.
Assumptions about long-term survival after elective 
surgery
Most of the studies used national mortality rates for the
average population as proxy for long-term survival after
elective surgery, but some studies made more realistic
assumptions. Wanheinen et al. [17] assumed that the
mortality in treated AAA patients were 2.05 times the rates
in the age-matched normal population because of high
comorbidity rates in AAA patients. Lee et al. [20] adjusted
the annual mortality rates to take account of expected
excess mortality in patients with dialysis-dependent renal
failure, stroke, myocardial infarction or major amputa-
tion. Henriksson et al. [18] and Soisalon-Soininen et al.
[15] used local mortality data for AAA patients for 5 years
and 17 years, respectively, and carried out survival analy-
sis using statistical methods (Weibull or actuarial) in their
estimation of life-years gained.
Assumptions about quality of life (QOL) and QALY after 
elective surgery
Seven of the decision analytic studies calculated ICER as
the incremental cost per gained QALY. These studies
implicitly assumed that postoperative QOL (and after
recovery) was similar to the QOL of the age-matched gen-
eral population. Only one study (Lee et al. [20]) included
the reduced QOL experienced by patients with major sur-
gical complications.
Only two studies carried out sensitivity analyses of QOL
assumptions. Wanheinen et al. [17] assumed a short-term
reduction in QOL due to anxiety experienced before
untrasonography. They estimated a reduction of 5% in the
first-year QALY, which was outweighed by uncertainty in
the long term. Henriksson et al. [18] did a multiway sen-
sitivity analysis in which QOL was allowed to vary sto-
chastically according to a pre-specified statistical
distribution, but it was not possible to distinguish the
effect.
Discussion
The purpose of this review was to carry out a critical assess-
ment of cost-effectiveness studies of screening older males
for AAA. Based on our review of 16 studies, it seems that
most of the health economic analyses of screening for
AAA employed "optimistic" assumptions about the cost
effectiveness of AAA screening.
The MASS cost-effectiveness study at four years [8] has the
highest quality, but this single study does not provide
enough information to assess the cost-effectiveness of
AAA screening. MASS did not collect information on
QALY gains, and endovascular aortic aneurysm repair was
not used in the trial. The time perspective in MASS was
four years, and a modelling approach is needed to assess
long-term cost consequences and perform detailed sensi-
tivity analyses.
In all published decision analytic models of AAA screen-
ing hypothetical patients with an AAA ≥ 5.5 cm were
assumed to face a constant probability of rupture (average
for males aged 65–79 years) no matter how many years
they have had a large AAA. In cohort simulations such a
constant probability of rupture gives a wrong distribution
of death over time and a mean age of males having emer-
gency surgery for ruptured AAA that is much too low. For
instance in Denmark the mean age of death from ruptured
AAA is 76 years (range 65–92) for males aged ≥ 65. One
way to "build memory" into a model is to implement
time dependency, but none of the modelling studies
seems to have done so. Accordingly, when underestimat-
ing the age of males dying of ruptured AAA in the non-
screening group the calculated number of "gained life-
years" due to screening and avoiding ruptures is too high.
Most of the health economic studies of AAA screening
only included short term hospital costs. Major implica-
tions for society due to comorbidity and severe surgical
complications (e.g. stroke or chronic renal failure) were
not included because most studies did not consider cost
after hospital discharge. Patient pathways after such
events can be very costly [24]. Furthermore, screening
might induce extra long term cost of treatment of those
unfit for surgery [9].
Economic evaluations did not incorporate evidence that
the lives of tobacco smokers are generally shorter thanBMC Cardiovascular Disorders 2008, 8:32 http://www.biomedcentral.com/1471-2261/8/32
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those of the general population, and that they have a
higher demand for health services (i.e. higher social and
health care costs) and a lower QOL in the remaining life-
years [25-27] (>90% of patients with AAA have a history
of smoking [3-5]).
There has been considerable interest in smoking cessation
programmes during the last decade. Successes in reducing
the number of smokers have been linked to potential sav-
ings in future health care costs [25-27]. Economic evalua-
tions of AAA screening seem to have ignored the
relationship between tobacco smoking and AAA inci-
dence. The incidence may even fall to levels that render
population screening ineffective in terms of lives saved, let
alone cost.
There is a lower prevalence of large AAAs in males who
have never smoked, so the potential benefit from screen-
ing non-smokers is small. The USA Preventive Services
Task Force recommends AAA screening in male smokers
only for this reason [28]. The possibility of screening only
male smokers could probably increase cost-effectiveness,
although some authors argue the benefit from targeted
screening is marginal compared with population screen-
ing [17].
All cost-utility studies assumed that patients with AAA
could return to a QOL comparable with the average pop-
ulation: there is only poor evidence for this assumption.
None of the randomised trials of AAA screening have col-
lected evidence about QOL before and after screening and
elective surgery in the screening group compared to the
average population (i.e. the non-screening group). Only
studies of QOL with poorer designs have been published.
Furthermore, the clinical literature of QOL after elective
repair that are being referred to seems to be in conflict
with public health evidence that smokers experience a
lower QOL in their remaining years of life compared to
the average population. At least more sensitivity analyses
should have been done to evaluate the possibility of lower
QOL due to comorbidity and severe surgical complica-
tions such as chronic renal failure, major amputation or
stroke.
Various other factors likely to reduce cost-effectiveness
were ignored in the economic evaluations. In most cases,
cost calculations were based on open repair and not on
endovascular aneurysm repair. Despite lack of evidence of
cost-effectiveness, this method of treating AAAs is being
used increasingly in many countries. It may reduce early
mortality more effectively, but it may substantially reduce
the cost-effectiveness of screening [29].
The possibility is that ad hoc detection of AAA cases will
gradually increase as imaging (mostly ultrasonography)
becomes more widely utilized for other reasons. This may
reduce the prevalent pool of undiagnosed AAAs and
hence screening effectiveness [30].
Our findings are in accordance with those of Campbell et
al. [31]; they reviewed cost-effectiveness studies of AAA
screening published between 1989 and 2003. They found
that "eight of the nine population screening models have
incorporated at least two assumptions, which would arti-
ficially favour a screening programme". This review by
Campbell et al. has not been updated; the search period
ended in 2003, and they excluded studies conducted
alongside trials, which is a major source of evidence for
cost-effectiveness. Our review includes ten new cost-effec-
tiveness analyses, and only four studies overlap. Our
review gives the "whole" picture of cost-effectiveness of
AAA screening, which have not been presented before.
The individual conclusions of cost effectiveness cannot be
rejected on the basis of this systematic review, but we can
seriously challenge the assumptions on which the studies
of cost-effectiveness are based. Our review leaves little
doubt that the reported cost-effectiveness ratios of AAA
screening in most cases have been too low.
Our findings should have implications for future research
recommendations in cardiovascular medicine and sur-
gery. It appears that existing analyses have overrated the
advantages of AAA screening in terms of the expected
number of gained life-years/QALYs and cost of a screening
programme. Different patient pathways after surgery are
ignored, and sensitivity analyses of long-term QOL after
surgery are not satisfactory.
We therefore strongly recommend that an "updated" cost-
effectiveness analysis should be carried out based on more
realistic assumptions.
Conclusion
This review indicates that most of the existing health eco-
nomic evaluations have employed a number of "optimis-
tic" assumptions in favour of AAA screening, and included
only few sensitivity analyses that assessed less optimistic
assumptions. Further analyses of cost-effectiveness of AAA
screening are recommended.
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